Interesting. Record Revenue- but
1. Sequential Quarter on Quarter patients flat (although it looks good compared to PY)
2. Sequential Q1 to Q2 Patients/week even (although compared to PY Q2 again it looks impressive)
3. Sequential Revenue Growth Rate Q1 to Q2 slowed slightly
4.Sequential Q1 to Q2 revenue from reorder less than 3% growth-
5. GAAP non GAPP losses increased

Compared Q2 2010 to Q 2 2009 it looks impressive. But from my key hole view the sequential numbers are not so great.
I continue to hear (as posted earlier) difficult time consuming placement, benefit not percieved given risk of hemolysis and eschemia.
Status of Protect II - enrollment of 28? Still not at halfway mark? I am not sure what they are going to find AT the halfway mark?

Not sure why the stock is up, down or sideways- but I would not expect very postitive reception.